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Abstract The transcription factor c-Myc plays critical
roles in cancer development and progression through
regulating expression of targeted genes. Lactate dehy-
drogenase A (LDHA), which catalyzes the conversion of
L-lactate to pyruvate in the final step of anaerobic gly-
colysis, is frequently upregulated in pancreatic cancer.
However, little is known about the effects of c-Myc–
LDHA axis in the progression of pancreatic cancer. In
this study, we found that c-Myc and LDHA are con-
comitantly overexpressed in pancreatic cancer cell lines
and clinical specimens. c-Myc overexpression and LDHA
overexpression were correlated with TNM stage and tu-
mor size and indicated poor prognosis in patients with
pancreatic cancer. Knockdown of c-Myc reduced the
protein expression of LDHA, lactate production and
glucose consumption, and silencing of LDHA mimicked
this effect. Meanwhile, reduced c-Myc–LDHA signaling
resulted in decreased tumor growth and metastasis in
pancreatic cancer. Treatment with 2-Deoxy-D-glucose, an
inhibitor of anaerobic glycolysis, completely blocked the
oncogenic roles of c-Myc–LDHA signaling. Taken
together, dysregulated c-Myc–LDHA signaling plays
important roles in aerobic glycolysis and facilitates
tumor progression of pancreatic cancer.
Keywords c-Myc  LDHA  Warburg effect 
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Introduction
Pancreatic cancer is one of the most common malignancies
worldwide, and its incidence is increasing annually, espe-
cially in industrialized countries [1]. Although great
achievements have made in early diagnosis, surgical re-
section and systemic chemotherapy for pancreatic cancer,
the overall 5-year survival rate in patients with pancreatic
cancer remains at 6 % [2]. The disappointing survival rate
and poor prognosis of pancreatic cancer indicate the ag-
gressive nature of this disease. Therefore, it is of great
importance to understand the molecular mechanisms that
underlie the initiation and progression of pancreatic cancer
[3, 4].
c-Myc is a crucial transcription factor involved in the
regulation of multiple cellular functions including cell
growth, apoptosis, differentiation, protein synthesis, and
cell adhesion and energy metabolism [5]. The involvement
of c-Myc in such a broad spectrum of cellular functions
might be explained by the data that c-Myc binds 10–15 %
of all promoter regions [6]. However, the protein encoded
by this gene is frequently deregulated in several types of
human tumors [7, 8]. Because c-Myc exerts its functions
mainly through transcriptional regulation of target genes
that associate with tumorigenesis and progression via dif-
ferent mechanisms, c-Myc is therefore an attractive target
for cancer therapy [9].
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An increase in aerobic glycolysis, which is the ability to
switch from an oxidative metabolism to glycolysis and the
production of lactate even when oxygen is plentiful
(Warburg effect), is a key characteristic of solid tumors,
including pancreatic cancer [10]. Because it is closely
associated with tumor growth and progression, aerobic
glycolysis is considered a metabolic signature for invasive
cancer [11]. Lactate dehydrogenase A (LDHA), which
catalyzes the last step of anaerobic glycolysis, is abnor-
mally expressed in many human cancers including pan-
creatic cancer [12], hepatocellular carcinoma [13] and
breast cancer [14]. c-Myc can regulate aerobic glycolysis
through targeting the metabolic enzymes including HK2,
PFKL LDHA, PDK1, etc. [15]. However, the precise role
of c-Myc–LDHA axis in aerobic glycolysis and tumor cell
phenotype of pancreatic cancer remains unclear.
In this study, we determined the expression pattern and
clinical significance of c-Myc–LDHA axis in pancreatic
cancer. We found that up-regulated c-Myc–LDHA axis is
closely associated with tumor progression and indicates a
poor prognosis in pancreatic cancer. Suppression of
c-Myc–LDHA axis caused reduced aerobic glycolysis and
further contributed to growth arrest and inability of inva-
sion in pancreatic cancer cells.
Materials and methods
Cell culture and reagents
Human pancreatic cancer cells including AsPC-1, BxPC-3,
Capan-2, CFPAC-1, HPAC, PANC-1, MiaPaca2 and
SW1990 were cultured in specific media supplemented
with 10 % (v/v) fetal bovine serum (FBS), 100 U/mL,
penicillin and 100 lg/mL streptomycin at 37 C in a hu-
midified incubator with 5 % CO2. 2-DG (Sigma, USA) was
diluted to preferable concentrations in culture medium
before use.
Immunohistochemistry
Tissue microarray (TMA) that contained 90 cases of pan-
creatic cancer tissues used in current study was purchased
from Shanghai Outdo Biotech Inc (HPan-Ade180Sur-01).
The collection of human specimens was approved by the
Medical Institutional Review Boards in Shanghai and in
accordance with the highest ethical guidelines. The follow-
up time was calculated from the date of surgery to the date
of death, or the last known follow-up. The TMA of pan-
creatic cancer was deparaffinized with xylene and rehy-
drated using graded ethanol. After washing in phosphate-
buffered saline (PBS) for three times, antigen retrieval and
neutralization of endogenous peroxidase were performed,
followed by incubation with 5 % bovine serum albumin for
1 h. After rinsing with PBS for three times, slides were
incubated overnight at 4 C with primary antibody (c-Myc,
Abcam, #32072; LDHA, Proteintech, #19987-1-AP). After
washing in PBS for three times, the sections were incubated
with HRP-labeled anti-rabbit secondary antibody for 1 h at
room temperature. Visualization was performed by 3, 30-
diaminobenzidine tetrahydrochloride (DAB) and counter-
stained by hematoxylin. Scoring was conducted according
to the positive area and the intensity score as follows. The
positive area: 0–10 % scored 0; 11–35 % scored 1;
36–70 % scored 2; more than 70 % scored 3 and intensity
score: no staining scored 0, weakly staining scored 1,
moderately staining scored 2 and strongly staining scored 3.
The final score was designated as the score of positive
area 9 intensity score: ‘‘-’’ for a score of 0–1, ‘‘?’’ for a
score of 2–3, ‘‘??’’ for a score of 4–6 and ‘‘???’’ for a
score of[6; low expression was defined as a total score\4
and high expression with a total score C4. These scores
were determined independently by two senior pathologists.
siRNA transfection
The sequence of two siRNAs targeting c-Myc or LDHA was
denoted as follows: si-Myc-1 (TACGGAACTCTTGTGCG-
TAAGC), si-Myc-2 (GCTTCACCAACAGGAACTATGC);
si-LDAH-1 (TTGTTGATGTCATCGAAG), si-LDHA-2
(GGGTCCTTGGGGAACATG). The negative control indi-
cated as si-Ctrl was non-homologous to any human genome
sequences. The AsPC-1 and SW1990 cells were transfected
with 50 nMof siRNAand5 ll ofRNAi-Mate according to the
manufacturer’s instructions (GenePharma, Shanghai, China).
Cells were cultured for 48 h, and the interference efficiency
was detected by western blotting.
Quantitative real-time PCR
Total RNA was isolated from pancreatic cancer cell lines by
using the Trizol reagent (Invitrogen) and reverse transcrip-
tion was performed using the PrimeScript RT-PCR kit
(Takara, Japan). The mRNA levels of detected genes were
quantified on an ABIPrism-7500 Sequence Detector System
(ABI, Applied Biosystems, USA). b-Actin was used as an
internal control. Relative expression of c-Myc or LDAHwas
normalized to the expression of b-actin, which yielded a





actin sense 50-GTTGTCGACGACGAGCG-30, b-actin an-
tisense 50-GCACAGAGCCTCGCCTT-30. All reactions
were run in triplicate.
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In vitro cell proliferation assay
Cell Counting Kit-8 (CCK8, Dojindo, Japan) assay was used
to measure cell proliferation in AsPC-1 and SW1990 cells.
Briefly, after transfectionwith si-Ctrl and targeted siRNAs for
48 h, AsPC-1 and SW1990 cells (3000 per well) were plated
in 96-well plates with RPMI1640 containing 10 %FBS. Each
sample had four replicates. At the indicated time points, cells
were incubated in media containing 10 % CCK8 for 1 h at
37 C. The absorbance of the solution was read at 490 nm
using a Power Wave XS microplate reader (BIO-TEK).
Cell migration and invasion assays
The invasive potential of AsPC-1 and SW1990 cells was
measured by transwell model (Corning, USA) according to
the manufacturer’s instructions. Briefly, 2 9 104 cells in
100 ll medium were seeded into the upper compartment of
the transwell inserts. Importantly, the invasion assay was
performed with matrigel-coated filters (BD Bioscience,
USA). The lower chambers were filled with 800 ll of RPMI-
1640 medium containing 2 % FBS. After the cells were in-
cubated for 16 h in cell migration assay and 40 h in cell
Fig. 1 Dysregulated c-Myc–LDHA axis is closely associated with
tumor progression and indicates a poor prognosis in pancreatic
cancer. Representative images of high c-Myc expression (a), low
c-Myc expression (b), high LDHA expression (c) and low LDHA
expression (d) in pancreatic cancer specimens, scale bar: 100 lm.
e Correlation between c-Myc and LDHA mRNA expression in
pancreatic cancer cell lines. f Immunohistochemical analysis of the
correlation between c-Myc and LDHA expression; P value was
calculated by the Spearman’s rank correlation test. g Kaplan–Meier
survival curves of pancreatic cancer patients according to the status of
c-Myc expression. h Kaplan–Meier survival curves of pancreatic
cancer patients according to the status of LDHA expression
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invasion assay, the non-invading cells that remained on the
upper surface were removed. The migrated and invaded cells
were fixed with 4 % paraformaldehyde and stained with
0.1 %crystal violet. The number of invaded cells was counted
under a light microscope in six random fields. Each ex-
periment was performed in triplicate.
Measurement of glucose and lactate
Lactate Colorimetric Assay Kit (BioVision) and Glucose
Colorimetric Assay Kit (Life technologies) were used ac-
cording to the manufacturer’s protocols to estimate the
intracellular glucose utilization and lactate concentration in
pancreatic cancer cells. The glucose utilization or lactate
production was estimated using a standard glucose
calibration curve prepared under the same condition.
Statistical analysis
Data were presented as the mean ± SD. The SPSS soft-
ware program (version 17.0; IBM Corporation) was used
for statistical analysis, and graphical representations were
performed with GraphPad Prism 5 (San Diego, CA) soft-
ware. The Chi-square test was used to analyze the overall
survival rate, and the difference in survival curves was
evaluated by the log-rank test. Correlations between c-Myc
and LDHA levels in pancreatic cancer were analyzed by
Spearman’s rank correlation. All other data were analyzed
using two-sided Student’s t test. P values \0.05 were
considered statistically significant.
Results
Dysregulated c-Myc–LDHA axis is closely associated
with tumor progression and indicates a poor
prognosis in pancreatic cancer
To observe the expression pattern of c-Myc–LDHA axis in
pancreatic cancer, we first used immunohistochemistry to
investigate c-Myc and LDHA protein levels in 90 pancreatic
cancer specimens and qRT-PCR to measure c-Myc and
LDHA mRNA levels in seven pancreatic cancer cell lines.
Immunohistochemical analysis showed that high c-Myc
expression andLDHAexpressionwere 65.56 and 70.00 % in
tested specimens, respectively (Fig. 1a–d); elevated c-Myc
expression andLDHAexpression are closely associatedwith
tumor size (P\ 0.001) and TNM stage (P\ 0.001)
(Table 1). Besides, we found a significant positive correla-
tion between mRNA levels of c-Myc and LDHA in pancre-
atic cancer cell lines (P\ 0.001, Fig. 1e). Consistent with
qRT-PCR results, there was also significant positive corre-
lation between c-Myc and LDHA in pancreatic cancer
specimens (P\ 0.001, Fig. 1f). Moreover, we tested the
clinical significance of c-Myc and LDHA in patients with
pancreatic cancer. Ninety pancreatic cancer patients with
clinical follow-ups were analyzed by Kaplan–Meier esti-
mation. The result indicated that tumorswith high expression
of c-Myc (P = 0.002, Fig. 1g) or LDHA (P = 0.008,
Fig. 1h) indeed significantly associated with poor overall
survival of pancreatic cancer patients. These findings
strongly indicate that c-Myc–LDHA axis plays a critical role
in pancreatic cancer development and progression and is a
potential valuable predictor for this disease.
Effects of c-Myc–LDHA axis on aerobic glycolysis
in pancreatic cancer cells in vitro
To demonstrate the effect of c-Myc–LDHA axis on aerobic
glycolysis in pancreatic cancer cells, we firstly silenced
c-Myc expression in AsPC-1 and SW1990 cells by siR-
NAs. As shown in Fig. 2a, knockdown of c-Myc resulted in
reduced LDHA expression, further confirming the regula-
tion of c-Myc in LDHA expression. And expectedly, sup-
pression of c-Myc also markedly inhibited aerobic
glycolysis as demonstrated by decreased glucose utilization
(Fig. 2b) and lactate production (Fig. 2c). To determine the
Table 1 Correlations between c-Myc or LDHA expression and
clinicopathologic features in patients with pancreatic cancer
Variable Expression of c-Myc Expression of LDHA
Low High P value Low High P value
Age
B60 years 16 26 0.495 15 27 0.268
[60 years 15 33 12 36
Gender
Female 12 21 0.771 11 22 0.600
Male 19 38 16 41
Tumor size
B4 cm 23 29 0.013* 23 29 0.001**
[4 cm 7 30 4 33
Tumor location
Head 17 34 1.000 15 36 0.909
Body/tail 12 24 11 25
TNM stage
I 20 20 0.005** 19 21 0.001**
II–III 10 37 7 40
Neuronal invasion
Yes 11 26 0.432 12 25 0.674
No 20 33 15 38
Histological grade
I–II 21 36 0.357 17 40 0.738
II–IV 6 17 6 17
The asterisk represents the P values with significant differences
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implications of c-Myc on aerobic glycolysis mediated by
LDHA, glucose utilization and lactate production were
further measured after treatment with LDHA siRNAs in
AsPC-1 and SW1990 cells (Fig. 2d). Indeed, inhibition of
LDHA also resulted in reduced aerobic glycolysis (Fig. 2f,
g). Collectively, these results suggest that c-Myc–LDHA
axis exhibits a critical role in regulation of aerobic gly-
colysis in pancreatic cancer.
Suppression of aerobic glycolysis induced by c-Myc–
LDHA axis inhibits tumor growth and progression
in pancreatic cancer cells in vitro
Switching to the aerobic glycolysis, also known as War-
burg effect, is a key characteristic of cancer metabolism
and is not only critical factor for tumor growth but also
essential for tumor metastasis [16]. Next, we determined
the effects of c-Myc–LDHA axis on tumor growth and
progression in AsPC-1 and SW1990 cells. As shown in
Fig. 3a, b, knockdown of c-Myc resulted in pronounced
decreased cell growth rate in both AsPC-1 and SW1990
cells. Using a Transwell model, we found the ability of cell
migration and invasion was also reduced by suppression of
c-Myc expression (Fig. 3c, d). Meanwhile, inhibition of
LDHA also mimicked the effects of c-Myc on cell prolif-
eration, migration and invasion (Fig. 3e–h). Given that the
aerobic glycolysis was significantly reduced by inhibition
of c-Myc–LDHA axis, we thereby hypothesized whether
c-Myc–LDHA axis functions through regulating the aero-
bic glycolysis. To test this hypothesis, cellular functions in
AsPC-1 and SW1990 cells were measured after treatment
with 2-Deoxy-D-glucose (2-DG), a glycolysis inhibitor.
The results showed that the disadvantage of tumor growth
and progression conferred by inhibition of c-Myc–LDHA
axis was completely abolished (Fig. 4a–h). Taken together,
these data suggest that decreased aerobic glycolysis ac-
counts for the tumor growth and progression induced by
c-Myc–LDHA axis.
Discussion
In the current study, we determined the critical roles of
c-Myc–LDHA axis in aerobic glycolysis and its cellular
functions in pancreatic cancer. First, we observed that
c-Myc and LDHA are concomitantly up-regulated in pan-
creatic cancer specimens and cell lines, and up-regulated
c-Myc expression and LDHA expression lead to poor
prognosis in pancreatic cancer patient. Second, suppression
of c-Myc resulted in decreased expression of LDHA, re-
duced aerobic glycolysis, growth arrest and inability of
invasion; meanwhile, knockdown of LDHA mimicked this
Fig. 2 Effects of c-Myc–
LDHA axis on aerobic
glycolysis in pancreatic cancer
cells in vitro. a The protein level
of c-Myc and LDHA was
detected by western blotting in
AsPC-1 and SW1990 cells after
c-Myc-specific siRNA
treatment. Glucose utilization
(b) and lactate production
(c) were measured after c-Myc
was silenced (si-Ctrl vs. si–c-
Myc-1 or si–c-Myc-2;
*P\ 0.05; **P\ 0.01). d The
interference efficiency of
LDHA was detected by western
blotting in AsPC-1 and SW1990
cells. Glucose utilization (e) and
lactate production (f) were
measured after LDHA was
silenced (si-Ctrl vs. si-LDHA-1
or si-LDHA-2; *P\ 0.05;
**P\ 0.01)
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effect. Third, inhibition of aerobic glycolysis abolished the
effects of c-Myc–LDHA axis on cell growth and metastasis
in vitro. Therefore, our findings demonstrated that c-Myc–
LDHA axis contributed to the Warburg effect, thus fa-
cilitating tumor development and progression in pancreatic
cancer.
Metabolic alternations in cancers not only support en-
ergy requirements but also provide enormous biosynthetic
needs [17]. c-Myc contributes to the glucose metabolic
reprogramming of tumor cells through several different
targets [6]. Briefly, through up-regulation of glucose
transporters, c-Myc increases the uptake of glucose; by
regulation of LDHA and the lactate transporter MCT1,
c-Myc promotes the Warburg effect; c-Myc also prevents
pyruvate to enter the TCA cycle by regulating pyruvate
dehydrogenase (PDK) expression [15]. Consistent with
this, c-Myc regulates LDHA expression in pancreatic
cancer and suppression of c-Myc significantly inhibited the
Warburg effect. In pancreatic cancer, it has been demon-
strated that the expression level of LDHA is up-regulated
in both clinical specimens and cell lines, and forced ex-
pression of LDHA promoted tumor growth and tumori-
genicity of pancreatic cancer [18]. Overexpressed LDHA
promotes the production of lactate and further contributes
to the acidification of tumor microenvironment [19]. A low
pH induced by extracellular acidification favors the acti-
vation of proteases, including MMPs [20] and urokinase-
type plasminogen activator [21], which ultimately result in
extracellular matrix degradation and facilitate cancer cells
to metastasis [22]. In our study, we found both c-Myc
expression and LDHA expression are closely associated
with tumor size and TNM stage and indicate poor prog-
nosis in patients with pancreatic cancer. Meanwhile, inhi-
bition of c-Myc–LDHA axis inhibits glucose utilization,
lactate production, cell proliferation, migration and inva-
sion. All these can be explained by the favorable tumor
microenvironment induced by c-Myc–LDHA axis fa-
cilitates tumor progression. However, because c-Myc reg-
ulates the expression of multiple targeted genes, it is hard
to draw a conclusion that this cell phenotype was mediated
by LDHA. And because LDHA expression is also regulated
by many other transcription factors including HIF1a [23]
and KLF4 [12] in pancreatic cancer, the oncogenic activity
of LDHA in Warburg effect and tumor progression also
remains to be further analyzed. Despite the presence of
these limits, we at least confirmed the oncogenic roles of
Fig. 3 Suppression of c-Myc–LDHA axis inhibits tumor growth and
progression in pancreatic cancer cells in vitro. Cell viability of AsPC-
1 cells (a) and SW1990 cells (b) was measured after c-Myc was
silenced. Cell migration (c) and invasion (d) abilities were measured
after c-Myc was silenced (si-Ctrl vs. si–c-Myc-1 or si–c-Myc-2;
*P\ 0.05; **P\ 0.01; ***P\ 0.001). Cell viability of AsPC-1
cells (e) and SW1990 cells (f) were measured after LDHA was
silenced. Cell migration (g) and invasion (h) abilities were measured
after LDHA was silenced (si-Ctrl vs. si-LDHA-1 or si-LDHA-2;
*P\ 0.05; **P\ 0.01; ***P\ 0.001)
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c-Myc–LDHA axis on tumor progression through enhanc-
ing Warburg effect.
In conclusion, our study provided both clinical and
mechanistic evidences supporting that c-Myc modulates
LDHA expression and that the c-Myc–LDHA axis exhibits
a critical role in aerobic glycolysis and tumor progression
in pancreatic cancer. Our research identified dysregulated
c-Myc–LDHA axis as a promising new molecular target for
the design of novel therapeutic to control development and
progression of pancreatic cancer.
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